

Temporary Benefit added to the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the unavailability of Nestle Materna Tablet (NPN 80082297), **Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)** manufactured by Jamieson Laboratories Ltd. will be considered as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*. This grouping was added to the Critical Supply Product List **November 27, 2024**.

As of **November 27, 2024**, all claims for **Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/provider/type/pharmacy/home.php.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Vistitan 0.03% Ophthalmic Solution (DIN 02429063) manufactured by Sandoz Canada Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **January 16, 2025**. The following grouping was removed from the Critical Supply Product List **December 17, 2024**.

BIMATOPROST

OPHTHALMIC SOLUTION

00002429063	VISTITAN 0.03%	SDZ	\$ 9.1936
00002324997	LUMIGAN RC 0.01%	ABV	\$ 11.8871

Alberta Blue Cross has confirmed that the shortage for Teva-Diltiazem XC 240 mg Extended-Release Tablet (DIN 02429330) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **January 20, 2025**. The following grouping was removed from the Critical Supply Product List **December 19, 2024**.

DILTIAZEM HCL

240 MG EXTENDED-RELEASE TABLET

00002429330	TEVA-DILTIAZEM XC	TEV	\$ 1.2212
00002256754	TIAZAC XC	VCL	\$ 1.7167

continued next page

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Teva-Diltiazem XC 360 mg Extended-Release Tablet (DIN 02429357) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **January 20, 2025**. The following grouping was removed from the Critical Supply Product List **December 19, 2024**.

DILTIAZEM HCL

360 MG EXTENDED-RELEASE TABLET

00002429357	TEVA-DILTIAZEM XC	TEV	\$ 1.2211
00002256770	TIAZAC XC	VCL	\$ 1.7140

Alberta Blue Cross has confirmed that the shortage for pms-Tetrabenzazine 25 mg Tablet (DIN 02402424) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **January 20, 2025**. The following grouping was removed from the Critical Supply Product List **December 19, 2024**.

TETRABENAZINE

25 MG TABLET

00002407590	APO-TETRABENAZINE	APX	\$ 3.3746
00002402424	PMS-TETRABENAZINE	PMS	\$ 3.3746
00002199270	NITOMAN	VCL	\$ 8.1816

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

